Rho GDP dissociation inhibitor-mediated disruption of Rho GTPase activity impairs lens fiber cell migration, elongation and survival.
To explore the role of the Rho GTPases in lens morphogenesis, we overexpressed bovine Rho GDP dissociation inhibitor (Rho GDI alpha), which serves as a negative regulator of Rho, Rac and Cdc42 GTPase activity, in a lens-specific manner in transgenic mice. This was achieved using a chimeric promoter of delta-crystallin enhancer and alpha A-crystallin, which is active at embryonic day 12. Several individual transgenic (Tg) lines were obtained, and exhibited ocular specific phenotype comprised of microphthalmic eyes with lens opacity. The overexpression of bovine Rho GDI alpha disrupted membrane translocation of Rho, Rac and Cdc42 GTPases in Tg lenses. Transgenic lenses also revealed abnormalities in the migration pattern, elongation and organization of lens fibers. These changes appeared to be associated with impaired organization of the actin cytoskeleton and cell-cell adhesions. At E14.5, the size of the Rho GDI alpha Tg lenses was larger compared to wild type (WT) and the central lens epithelium and differentiating fibers exhibited an abnormal increase of bromo-deoxy-uridine incorporation. Postnatal Tg eyes, however, were much smaller in size compared to WT eyes, revealing increased apoptosis in the disrupted lens fibers. Taken together, these data demonstrate a critical role for Rho GTPase-dependent signaling pathways in processes underlying morphogenesis, fiber cell migration, elongation and survival in the developing lens.
Maddala
Rupalatha
R
Department of Ophthalmology, Duke University School of Medicine, Durham, NC 27710, USA.
Reneker
Lixing W
LW
Pendurthi
Bhavana
B
Rao
Ponugoti V
PV
D000199:Actins / Q000378:metabolism; D000818:Animals; D000831:Animals, Newborn; D002417:Cattle; D002465:Cell Movement / Q000502:physiology*; D002470:Cell Survival / Q000187:drug effects; D003598:Cytoskeletal Proteins / Q000378:metabolism; D004622:Embryo, Mammalian; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005123:Eye / Q000196:embryology / Q000201:enzymology / Q000254:growth & development; D005124:Eye Abnormalities / Q000209:etiology / Q000473:pathology; D018628:Gene Dosage; D020730:Guanine Nucleotide Dissociation Inhibitors / Q000378:metabolism*; D007908:Lens, Crystalline / Q000187:drug effects* / Q000201:enzymology; D051379:Mice; D008822:Mice, Transgenic; D019076:Transgenes; D020741:rho GTP-Binding Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D062947:rho-Specific Guanine Nucleotide Dissociation Inhibitors
D000199:Actins; D003598:Cytoskeletal Proteins; D004791:Enzyme Inhibitors; D020730:Guanine Nucleotide Dissociation Inhibitors; D062947:rho-Specific Guanine Nucleotide Dissociation Inhibitors; D020741:rho GTP-Binding Proteins